The funds will be utilised for marketing initiatives, expanding the team, and exploring new ventures within the pharma supply chain and healthcare service provider sectors.
MrMed clocked the Annual Recurring Revenue (ARR) of over Rs 26 crore as of July 31st, 2023.
Devashish Singh, co-founder, Mr Med, said in a statement, “We are quite excited about the fundraise and are looking to utilise the funds for customer acquisition and team growth. While we are a frugal company, we recognise the challenges in the B2C domain.” He adds, “Our objective is to establish a profitable yet scalable brand in the super specialty healthcare space, ensuring the same level of customer service and operational excellence.”
Shanmugapraveen from Tamil Nadu Emerging Sector Seed Fund, said in a statement, “MrMed is an impactful venture in healthcare by making speciality treatments more affordable and bringing pricing transparency through their digital platform. We are delighted to partner with MrMed on their growth journey.”
